Parmax Pharma Complete Financial Statements

In FYNone, Parmax Pharma (PARMAX) reported revenue ₹16 Cr, net profit ₹-5 Cr and EPS ₹-12.70, with a net profit margin of -7.1%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Parmax Pharma stock price NSE .

11 Years of Data
2025 - 2015

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -7.14% 2025 data
Operating Margin 1.00% 2025 data
Return on Assets -10.53% 2025 data

Balance Sheet Ratios

Current Ratio 1.25 2025 data
Equity Ratio -10.53% 2025 data
Asset Turnover 1.47 2025 data

PARMAX Revenue, Net Profit & EBITDA — Year-on-Year Growth

PARMAX YoY (March 2025 vs Period) — revenue -42.9%, net profit -150.0%, expenses -32.1%.

Revenue Growth
-42.9%
Year-over-Year
Net Profit Growth
-150.0%
Year-over-Year
Expense Growth
-32.1%
Year-over-Year
Assets Growth
+26.7%
Year-over-Year
Liabilities Growth
+26.7%
Year-over-Year
Investing Cash Flow Growth
+50.0%
Year-over-Year

PARMAX Income Statement — Revenue, EBITDA & Net Profit

Parmax Pharma revenue ₹16 Cr, EBITDA ₹-3 Cr, net profit ₹-5 Cr, EPS ₹-12.70 (None) — net profit margin -7.1%. Explore PARMAX true value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Revenue 16 28 11 16 18 26 21 12 12 0 0
Expenses 19 28 14 13 16 23 19 11 11 0 0
EBITDA -3 0 -3 2 3 4 2 1 1 0 0
Operating Profit Margin % -27.00% 1.00% -31.00% 15.00% 14.00% 13.00% 8.00% 9.00% 9.00% 0.00% 0.00%
Depreciation 1 1 2 2 2 2 1 1 1 0 0
Interest 1 1 1 0 0 0 0 0 0 0 0
Profit Before Tax -5 -2 -6 0 0 1 1 0 0 0 0
Tax 0 0 0 0 0 1 0 0 0 0 0
Net Profit -5 -2 -6 0 0 1 0 0 0 0 0
Earnings Per Share (₹) -12.70 -5.60 -34.56 -0.28 0.38 2.02 1.15 0.21 0.00 -0.02 -0.01

PARMAX Balance Sheet — Assets, Liabilities & Shareholders' Equity

PARMAX total assets ₹19 Cr, total equity ₹-2 Cr, total liabilities ₹19 Cr (2025).

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
ASSETS
Total Assets 19 15 18 18 23 21 20 17 8 5
Current Assets 10 6 8 7 10 9 9 9 4 2
Fixed Assets 8 9 10 10 11 10 5 6 3 3
Capital Work in Progress 0 0 0 0 0 0 3 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0
Other Assets 10 6 8 8 12 11 11 11 5 3
LIABILITIES
Total Liabilities 19 15 18 18 23 21 20 17 8 5
Current Liabilities 8 6 5 5 6 5 5 2 1 1
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity -2 0 6 6 6 5 5 5 5 5
Share Capital 5 5 5 5 5 5 5 5 5 5
Reserves & Surplus -6 -4 1 2 1 1 0 0 0 0

PARMAX Cash Flow Statement — Operating, Investing & Financing

Parmax Pharma operating cash flow ₹-1 Cr, investing ₹-1 Cr, financing ₹1 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -1 0 0 1 4 3 1 4 -1 0 0
Investing Activities -1 -2 -1 -2 -3 -2 -3 -4 0 0 0
Financing Activities 1 1 0 -1 0 0 3 1 1 0 0
Net Cash Flow 0 0 -1 -2 1 0 1 1 0 0 0